Breast reconstruction: sorting out the options.

R. Zienowicz

2001-04-01

Abstract:

What problem does this paper attempt to address?

Abstract B049: Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy

Jun Bai,Fei Su,Chen Li,Yujing Wu,Jing Li,Xiaobin Zhao,Yongsheng Yang,Robert J Lee

DOI: https://doi.org/10.1158/2326-6074.tumimm23-b049

IF: 10.1

2023-12-02

Cancer Immunology Research

Abstract:Background: Tumor immunotherapy has shown promising efficacy in various types of cancer. However, the effectiveness of immunotherapy is often limited by the immune-suppressive microenvironment within tumors. To address this challenge, we developed a method of intratumoral injection using lipid nanoparticles (LNPs) to deliver Toll-like receptor 7, 8, and 9 agonists. LNPs effectively enhance immune activation while reducing systemic responses by increasing drug retention within the tumor. Methods: We encapsulated 30nt-CpG and Resiquimod into LNPs (QTsomeTM). Subcutaneous inoculation of 2 × 106 MC38 cells was performed in mice. Once the average tumor volume reached approximately 100mm3, we divided 15 mice into 3 groups based on tumor volume. Intratumoral injections began on the same day of grouping, with a dosage of 1mg/kg (5 injections every 3 days). Tumor volume and body weight were measured twice a week. We conducted two parallel experiments, each with 7 mice for the MC38 model and 8 mice for the B16 melanoma model in each group, to compare the efficacy of 26nt-CpG and 30nt-CpG. Results: On the 15th day post-dosing, the tumor growth inhibition rate (TGI) was 79.9% (P<0.001), resulting in a 73.7% increase in survival rate. LNP-delivered 26nt-CpG demonstrated a TGI rate of 75.4% (P<0.001), while 30nt-CpG showed a TGI of 81.9% (P<0.001). Interestingly, the 26nt-CpG group exhibited faster weight gain, indicating better safety. In the mouse B16 melanoma model, LNP-delivered 26nt-CpG achieved a TGI rate of 75.2% (P<0.001), slightly higher than 30nt-CpG (71.0%, P<0.001), and also resulted in faster weight gain. Conclusion: In conclusion, the use of LNP-delivered Toll-like receptor agonists demonstrated excellent tumor therapeutic effects and good safety in mouse models. Activation of Toll-like receptors effectively stimulated immune cells such as CD8+ T cells and NK cells, enhancing their ability to kill tumor cells. Direct injection of LNPs into the tumor improved this effect while reducing systemic side effects. This drug holds promise as a broad-spectrum anti-tumor treatment and may have potential for expanding the indications of existing tumor immunotherapies. Citation Format: Jun Bai, Fei Su, Chen Li, Yujing Wu, Jing Li, Xiaobin Zhao, Yongsheng Yang, Robert J Lee. Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B049.

oncology,immunology
Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Ya-Nan Tan,Jian-Dong Huang,Yong-Peng Li,Shan-Shan Li,Min Luo,Jie Luo,Anne Wing-Mui Lee,Li Fu,Fu-Qiang Hu,Xin-Yuan Guan

DOI: https://doi.org/10.1002/adhm.202101496

IF: 10

2021-01-01

Advanced Healthcare Materials

Abstract:The major obstacles of anti‐PD therapy in metastatic tumors are limited drug delivery in primary tumors and metastatic foci, and the lack of tumor‐infiltrating lymphocytes (TILs). Here, the authors constructed a novel cellular membrane nanovesicles platform (M/IR NPs) based on homologous targeting and near‐infrared (NIR) responsive release strategy to potentiate PD‐1/PD‐L1 blockade therapy against metastatic tumors. In tumor‐bearing mice, biomimetic M/IR NPs targeted both primary tumors and their lung metastases. Upon laser irradiation, M/IR NPs reduced cancer‐associated fibroblasts (CAFs) in tumor microenvironment, thus increasing the penetration of TILs. When shed from homologous tumor cell membranes, positively charged nanoparticles (IR NPs) core can capture released tumor‐associated antigens, thereby enhancing the antigen‐presenting ability of DCs to activate cytotoxic T lymphocytes. When the photothermal conversion temperature under NIR‐laser is higher than 42 °C, M/IR NPs initiated the rupture of cell membranes and the responsive release of PD‐1/PD‐L1 inhibitor BMS, which significantly attenuated tumor‐associated immunosuppression and synergistically induced T cellular immunity to inhibit the tumor growth and metastasis. Overall, biomimetic M/IR NPs can improve the targeting and therapeutic efficacy of anti‐PD therapy in primary tumors and metastases, opening up a new avenue for the diagnosis and treatment of metastatic tumors in the future.
Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

M. Jacyna,H. Thomas

DOI: https://doi.org/10.1136/pgmj.66.782.1000

1990-12-01

Postgraduate Medical Journal

Abstract:It has been realized for more than fifty years that patients receiving blood transfusions are at risk of developing hepatitis.' Attention to the possible causes of hepatic injury associated with blood transfusion excluded non-infectious problems, such as hepatic congestion, iron overload or chemical contaminants. Further studies in humans and animals soon confirmed that the hepatitis was due to a filterable infectious agent, too small to be anything larger than a virus.2 Serological tests for the viruses causing hepatitis B were developed in 1965 and for hepatitis A in 1973, and it was then realized that post-transfusion hepatitis was not related to either of these agents, or to any other known viruses.3 At this time, the term 'non-A non-B' hepatitis was first coined in an attempt to label this presumed hepatic infection. Identifying the agent responsible so that serological tests can be developed to screen blood and blood products for the presence of this agent is of prime importance, as non-A non-B (NANB) hepatitis is a major cause ofmorbidity. Acute fulminant NANB hepatitis has a higher fatality rate than any other form of viral hepatitis,4 and it has also been estimated that between 40-50% ofpatients acquiring NANB infection will develop chronic hepatitis, with 15-20% of these subjects progressing to cirrhosis.5 It has been estimated that in the USA approximately 6000 patients per annum develop cirrhosis as a direct consequence ofchronic NANB hepatitis.6 For the past decade, many groups of workers have endeavoured to identify the agent(s) responsible for this disease. In spite of the spectacular advances in molecular biology which have paralleled the same period, it is only within the past 2 years that a breakthrough has occurred. Part of the genome of an RNA virus (related to the togaand flaviviridae) that is responsible for many, though not all, cases ofNANB infection has been sequenced. This has been labelled hepatitis C virus, and studies indicate that it is responsible for approximately 70-95% of cases of parenterally transmitted non-A non-B hepatitis. This still leaves a significant proportion of cases presumed due to another NANB agent. Within the past year, molecular biologists in the USA have also cloned a different RNA virus which is believed to be responsible for the most cases of enterally transmitted NANB infections, and has been provisionally termed hepatitis E.6a Although identification and characterization of the NANB agents is not yet complete, attempts have still been made to treat this disease, in view of the high morbidity associated with this disease. Recent trials of alpha-interferons have given very encouraging results and hold out hope for a significant improvement in the prognosis of affected individuals. This review looks at recent studies on the nature of this disease, the latest attempts at isolating the causative agent(s), and, lastly, attempts to suppress and/or eliminate this infection.
Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors.

Lei-Ming Cao,Nian-Nian Zhong,Yao Xiao,Guang-Rui Wang,Zi-Zhan Li,Ze-Min Cai,Bing Liu,Chun Xu,L. Bu

DOI: https://doi.org/10.1002/smll.202308731

IF: 13.3

2024-02-07

Small

Abstract:Immunotherapy has emerged as a potent strategy in cancer treatment, with many approved drugs and modalities in the development stages. Despite its promise, immunotherapy is not without its limitations, including side effects and suboptimal efficacy. Using nanoparticles (NPs) as delivery vehicles to target immunotherapy to lymph nodes (LNs) can improve the efficacy of immunotherapy drugs and reduce side effects in patients. In this context, this paper reviews the development of LN-targeted immunotherapeutic NP strategies, the mechanisms of NP transport during LN targeting, and their related biosafety risks. NP targeting of LNs involves either passive targeting, influenced by NP physical properties, or active targeting, facilitated by affinity ligands on NP surfaces, while alternative methods, such as intranodal injection and high endothelial venule (HEV) targeting, have uncertain clinical applicability and require further research and validation. LN targeting of NPs for immunotherapy can reduce side effects and increase biocompatibility, but risks such as toxicity, organ accumulation, and oxidative stress remain, although strategies such as biodegradable biomacromolecules, polyethylene glycol (PEG) coating, and impurity addition can mitigate these risks. Additionally, this work concludes with a future-oriented discussion, offering critical insights into the field.

Medicine,Materials Science
Modulating Elasticity of Liposome for Enhanced Cancer Immunotherapy

Pengfei Yuan,Xiaodie Yan,Xiaoqing Zong,Xiaodi Li,Caiqi Yang,Xinjie Chen,Yuchao Li,Yaoqi Wen,Tianci Zhu,Wei Xue,Jian Dai

DOI: https://doi.org/10.1021/acsnano.4c09094

IF: 17.1

2024-08-14

ACS Nano

Abstract:Cancer immunotherapy has emerged as a promising approach to cancer treatment in recent years. The physical and chemical properties of nanocarriers are critical factors that regulate the immune activation of antigen-presenting cells (APCs) in the tumor microenvironment (TME). Herein, we extensively investigated the behavior of liposome nanoparticles (Lipo-NPs) with different elasticities, focusing on their interaction with immune cells and their transport mechanisms from tumors to tumor-draining lymph nodes (tdLNs). Successfully preparing Lipo-NPs with distinct elastic properties, their varied behaviors were observed, concerning immune cell interaction. Soft Lipo-NPs exhibited an affinity to cell membranes, while those with medium elasticity facilitated the cargo delivery to macrophages through membrane fusion. Conversely, hard Lipo-NPs enter macrophages via classical cellular uptake pathways. Additionally, it was noted that softer Lipo-NPs displayed superior transport to tdLNs in vivo, attributed to their deformable nature with lower elasticity. As a result, the medium elastic Lipo-NPs with agonists (cGAMP), by activating the STING pathway and enhancing transport to tdLNs, promoted abundant infiltration of tumor-infiltrating lymphocytes (TILs), leading to notable antitumor effects and extended survival in a melanoma mouse model. Furthermore, this study highlighted the potential synergistic effect of medium elasticity Lipo-NPs with immune checkpoint blockade (ICB) therapy in preventing tumor immune evasion. These findings hold promise for guiding immune-targeted delivery systems in cancer immunotherapy, particularly in vaccine design for tdLNs targeting and eradicating metastasis within tdLNs.
A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer

Kaiming Li,Xiaolin Li,Jie Wu,Haisi Wu,Min Wu,Yupeng Zhou,Ya Lin,Yifan Zou,Xiqun Jiang,Huae Xu

DOI: https://doi.org/10.1002/adfm.202404956

IF: 19

2024-06-27

Advanced Functional Materials

Abstract:A novel nanovaccine (dClip‐LNP/siRNA) based on T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM3) silencing and Toll‐like receptors (TLRs) activation nanoadjuvant (LNP/siRNA) and desialylated cancer cell membrane antigens (dClip) is developed. This nanovaccine effectively promotes dendritic cell (DC) maturation and activation while providing tumor antigens. Importantly, the nanovaccine significantly activates anti‐tumor immune responses, leading to the suppression of tumor growth and prevention of tumor occurrence. Cancer vaccines represent a promising form of immunotherapy employed in the treatment of cancer. However, their efficiency in eliciting immune responses is limited, and satisfactory results have yet to be achieved. Optimizing adjuvants and antigens is an important approach to promoting the anti‐tumor efficacy of cancer vaccines. Here, a novel nanoadjuvant (LNP/siRNA) designed to silence T‐cell immunoglobulin and mucin‐domain containing‐3 (TIM3) and activate Toll‐like receptors (TLRs) is presented. The LNP/siRNA demonstrates significant potential in promoting dendritic cell (DC) maturation and enhancing the anti‐tumor response. Furthermore, desialylated cancer cell membrane is utilized as antigens, providing a variety of tumor antigens for DCs and enhancing their function. Additionally, they are integrated to create a core‐shell structured nanovaccine (dClip‐LNP/siRNA) through coextrusion, which collectively enhances the cross‐presentation ability of DCs, thus achieving a dual enhancement strategy. The dClip‐LNP/siRNA significantly silences TIM3 expression in DCs and promotes antigen presentation by DCs. Besides, dClip‐LNP/siRNA significantly promotes the activation of T cells in lymph nodes and induces robust and durable anti‐tumor immunity in tumor sites to eliminate established B16‐OVA tumors, prevent tumor occurrence, and suppress tumor lung metastasis. The dClip‐LNP/siRNA is also suitable for combination with adoptive OT‐I cell therapy to enhance cancer immunotherapy. The dClip‐LNP/siRNA represents a robust vaccine platform for personalized cancer immunotherapy.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling

Shunli Fu,Lili Chang,Shujun Liu,Tong Gao,Xiao Sang,Zipeng Zhang,Weiwei Mu,Xiaoqing Liu,Shuang Liang,Han Yang,Huizhen Yang,Qingping Ma,Yongjun Liu,Na Zhang

DOI: https://doi.org/10.1038/s41467-023-38014-6

2023-04-19

Abstract:Targeting tumour immunosuppressive microenvironment is a crucial strategy in immunotherapy. However, the critical role of the tumour lymph node (LN) immune microenvironment (TLIME) in the tumour immune homoeostasis is often ignored. Here, we present a nanoinducer, NIL-IM-Lip, that remodels the suppressed TLIME via simultaneously mobilizing T and NK cells. The temperature-sensitive NIL-IM-Lip is firstly delivered to tumours, then directed to the LNs following pH-sensitive shedding of NGR motif and MMP2-responsive release of IL-15. IR780 and 1-MT induces immunogenic cell death and suppress regulatory T cells simultaneously during photo-thermal stimulation. We demonstrate that combining NIL-IM-Lip with anti-PD-1 significantly enhances the effectiveness of T and NK cells, leading to greatly suppressed tumour growth in both hot and cold tumour models, with complete response in some instances. Our work thus highlights the critical role of TLIME in immunotherapy and provides proof of principle to combine LN targeting with immune checkpoint blockade in cancer immunotherapy.
Abstract 6740: Next-generation LNPs induce effective anti-tumor T cell responses

Douglas G. Millar,Matthew J. Gold,Kirsten Olsen,Yu Wu,Yury Karpov,Robert Nechanitzky,Haritha Menon,Rajesh Krishnan,Robert Georgantas,Pamela Ohashi,Natalia Martin-Orozco

DOI: https://doi.org/10.1158/1538-7445.am2024-6740

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract mRNA immunotherapies have gained interest for the treatment of tumors from various origins, however, their ability to provide long -term durable tumor control has been underwhelming. Here we report that novel mRNA lipid nanoparticle (LNP) vaccinations induce robust expansion of antigen-specific T cells, although this does not always correlate with their ability to infiltrate and kill solid tumors. Using a portfolio of novel ionizable lipids and a robust in vivo model that reliably identifies LNPs with prominent anti-tissue T cell activity we have identified a putative LNP candidate that provides long term tumor control in a murine syngeneic tumor model. We utilized the model antigen glycoprotein (Gp), from the lymphocytic choriomeningitis virus (LCMV), and produced mRNA encoding the immunodominant epitopes gp3333-41, gp6161-80 and gp276276-286 (3GP-mRNA). This mRNA was encapsulated in various novel LNP formulations and administered i.m. into naïve C57Bl/6 mice to track the induction of a robust CD8+ T cell response identified using tetramers to gp33 and gp276. Successful candidate LNPs were then tested in the RIPgp model of autoimmune diabetes. RIPgp transgenic mice express LCMV-Gp in the pancreatic β cells and offer a robust assay for the ability to induce antigen-specific T cells capable of breaking self-tolerance and infiltrating and killing target tissue. Utilizing the RIPgp model to screen LNP candidates we identified a lead candidate, C2-5A, that both induced a robust expansion of antigen-specific T cells and tissue destruction. When utilized in a colon adenocarcinoma model expressing the LCMV-Gp antigen (MC38-Gp), therapeutic dosing of LNP C2-5A as a monotherapy lead to long term tumor clearance in 40% of the treated animals. We believe this screening platform allows the selection of LNP candidates capable of breaking self-tolerance, and one such candidate C2-5A provides a potent vehicle and adjuvant for mRNA based cancer vaccines. Citation Format: Douglas G. Millar, Matthew J. Gold, Kirsten Olsen, Yu Wu, Yury Karpov, Robert Nechanitzky, Haritha Menon, Rajesh Krishnan, Robert Georgantas, Pamela Ohashi, Natalia Martin-Orozco. Next-generation LNPs induce effective anti-tumor T cell responses [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6740.

oncology
Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Mingqi Liu,Yang Feng,Yougong Lu,Renqi Huang,Ying Zhang,Yanan Zhao,Ran Mo

DOI: https://doi.org/10.1126/sciadv.adk2444

IF: 13.6

2024-03-15

Science Advances

Abstract:Cancer vaccines show huge potential for cancer prevention and treatment. However, their efficacy remains limited due to weak immunogenicity regarding inefficient stimulation of cytotoxic T lymphocyte (CTL) responses. Inspired by the unique characteristic and biological function of high-density lipoprotein (HDL), we here develop an HDL-mimicking nanovaccine with the commendable lymph-targeted capacity to potently elicit antitumor immunity using lipid nanoparticle that is co-loaded with specific cancer cytomembrane harboring a collection of tumor-associated antigens and an immune adjuvant. The nanoparticulate impact is explored on the efficiency of lymphatic targeting and dendritic cell uptake. The optimized nanovaccine promotes the co-delivery of antigens and adjuvants to lymph nodes and maintains antigen presentation of dendritic cells, resulting in long-term immune surveillance as the elevated frequency of CTLs within lymphoid organs and tumor tissue. Immunization of nanovaccine suppresses tumor formation and growth and augments the therapeutic efficacy of checkpoint inhibitors notably on the high-stemness melanoma in the mouse models.

multidisciplinary sciences
Lymph Node Delivery Strategy Enables the Activation of Cytotoxic T Lymphocytes and Natural Killer Cells to Augment Cancer Immunotherapy.

Tong Gao,Shuang Liang,Yang Liu,Zipeng Zhang,Na Zhang,Rui Yang,W. Mu,Dandan Jiang,Yongjun Liu,Shunli Fu

DOI: https://doi.org/10.1021/acsami.1c03709

2021-05-06

Abstract:Lymph nodes are the main sites for immune activation and surveillance. Effective delivery of immunomodulators into lymph nodes to trigger antitumor immunity is essential for cancer treatment. Here, we propose a lymph node delivery strategy to modulate the immune response by activating cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells simultaneously. Novel pH/redox dual-sensitive micelles were prepared using poly(l-histidine)-poly(ethylene glycol) (PLH-PEG) as a skeleton, which can effectively deliver immunomodulators to the lymph nodes due to their suitable particle size. At 48 h after subcutaneous injection, the accumulation efficiency in lymph nodes increased 8.12-fold compared with the control group. Subsequently, Trp2/CpG-coloaded pH/redox dual-sensitive micelles (Trp2/CpG-NPs) acted on antigen-presenting cells, fully promoting CTL activation through dendritic cell antigen cross-presentation and macrophage repolarization. IL-15-loaded pH/redox dual-sensitive micelles (IL-15-NPs) were developed to activate the killing effect of NK cells by interacting with IL-15 receptors. In the tumor-bearing mice model, this lymph node delivery strategy showed significant antitumor efficiency and the tumor inhibition rate reached 93.76%. Meanwhile, the infiltration of CTLs and NK cells in tumor tissues increased, and the immunosuppressive microenvironment was relieved by the repolarization of macrophages from M2-type to M1-type. Overall, this study highlighted the potential of the lymph node delivery strategy for cancer immunotherapy.

Medicine
Cationic Lipids‐Mediated Dual‐Targeting of Both Dendritic Cells and Tumor Cells for Potent Cancer Immunotherapy

Min Li,Han Zhou,Minghao Fang,Kun Qu,Yucai Wang

DOI: https://doi.org/10.1002/adfm.202306752

IF: 19

2023-09-02

Advanced Functional Materials

Abstract:By tuning nanoparticle (NP) surface charge, it is shown that NPs with moderately positive surface charge (≈20 mV) achieve efficient accumulation in tumors and lymph nodes and exhibit dual‐targeting ability to both dendritic cells (DCs) and tumor cells. The dual‐targeting nanomedicines for improving tumor antigen presentation by both DCs and tumor cells generate efficient antitumor immunity. Impaired antigen presentation either in dendritic cells (DCs) or tumor cells impedes the triggering of antitumor immunity or tumor cell killing, resulting in failures of multiple types of cancer immunotherapy. Herein, the strategy of using dual‐targeting nanomedicines to simultaneously improve the presentation of tumor antigens by both DCs and tumor cells is proposed. It is shown that tuning of surface charge of nanoparticles (NPs) by incorporating different amounts of cationic lipids alters the in vivo NP tissue accumulation and cellular targeting profiles. NPs with moderately positive surface charge (≈20 mV) achieve efficient accumulation in tumors and lymph nodes and dual‐targeting to both DCs and tumor cells. As a proof‐of‐concept demonstration, siRNA against YTH N6−methyladenosine RNA binding protein 1 (YTHDF1) is delivered by the dual‐targeting NPs to inhibit excessive antigen degradation in both DCs and tumor cells. For DCs, YTHDF1 downregulation promotes tumor antigen cross‐presentation and cross‐priming of antigen‐specific T cells. For tumor cells, it enhances the presentation of endogenous tumor antigens and hence improves both the recognition and killing of tumor cells by primed antigen‐specific T cells. The dual‐targeting nanomedicines generate efficient antitumor immunity.

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology
Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Liusheng Wu,Xiaoqiang Li,Xinye Qian,Shuang Wang,Jixian Liu,Jun Yan

DOI: https://doi.org/10.3390/vaccines12020186

2024-02-13

Vaccines

Abstract:In recent years, lipid nanoparticles (LNPs) have attracted extensive attention in tumor immunotherapy. Targeting immune cells in cancer therapy has become a strategy of great research interest. mRNA vaccines are a potential choice for tumor immunotherapy, due to their ability to directly encode antigen proteins and stimulate a strong immune response. However, the mode of delivery and lack of stability of mRNA are key issues limiting its application. LNPs are an excellent mRNA delivery carrier, and their structural stability and biocompatibility make them an effective means for delivering mRNA to specific targets. This study summarizes the research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity. The role of LNPs in improving mRNA stability, immunogenicity, and targeting is discussed. This review aims to systematically summarize the latest research progress in LNP delivery carrier-assisted targeted controlled release mRNA vaccines in tumor immunity to provide new ideas and strategies for tumor immunotherapy, as well as to provide more effective treatment plans for patients.

immunology,medicine, research & experimental
Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Ahmed E. I. Hamouda,Jessica Filtjens,Elisabeth Brabants,Daliya Kancheva,Ayla Debraekeleer,Jan Brughmans,Lotte Jacobs,Pauline M. R. Bardet,Elisabeth Knetemann,Pierre Lefesvre,Lize Allonsius,Mark Gontsarik,Ismael Varela,Marian Crabbé,Emile J. Clappaert,Federica Cappellesso,Aarushi A. Caro,Alícia Gordún Peiró,Luna Fredericq,Eva Hadadi,Mariona Estapé Senti,Raymond Schiffelers,Leo A. van Grunsven,Frank Aboubakar Nana,Bruno G. De Geest,Sofie Deschoemaeker,Stefaan De Koker,Florence Lambolez,Damya Laoui

DOI: https://doi.org/10.1038/s41467-024-54877-9

IF: 16.6

2024-12-06

Nature Communications

Abstract:Local delivery of mRNA-based immunotherapy offers a promising avenue as it enables the production of specific immunomodulatory proteins that can stimulate the immune system to recognize and eliminate cancer cells while limiting systemic exposure and toxicities. Here, we develop and employ lipid-based nanoparticles (LNPs) to intratumorally deliver an mRNA mixture encoding the cytokines interleukin (IL)−21 and IL-7 and the immunostimulatory molecule 4-1BB ligand (Triplet LNP). IL-21 synergy with IL-7 and 4-1BBL leads to a profound increase in the frequency of tumor-infiltrating CD8 + T cells and their capacity to produce granzyme B and IFN-γ, leading to tumor eradication and the development of long-term immunological memory. Mechanistically, the efficacy of the Triplet LNP depends on tumor-draining lymph nodes to tumor CD8 + T-cell trafficking. Moreover, we highlight the therapeutic potential of the Triplet LNP in multiple tumor models in female mice and its superior therapeutic efficacy to immune checkpoint blockade. Ultimately, the expression of these immunomodulators is associated with better overall survival in patients with cancer.

multidisciplinary sciences
Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response

Xiang Yu,Yanfeng Dai,Yifan Zhao,Shuhong Qi,Lei Liu,Lisen Lu,Qingming Luo,Zhihong Zhang

DOI: https://doi.org/10.1038/s41467-020-14906-9

IF: 16.6

2020-02-28

Nature Communications

Abstract:Abstract Targeted delivery of a nanovaccine loaded with a tumor antigen and adjuvant to the lymph nodes (LNs) is an attractive approach for improving cancer immunotherapy outcomes. However, the application of this technique is restricted by the paucity of suitable tumor-associated antigens (TAAs) and the sophisticated technology required to identify tumor neoantigens. Here, we demonstrate that a self-assembling melittin-lipid nanoparticle (α-melittin-NP) that is not loaded with extra tumor antigens promotes whole tumor antigen release in situ and results in the activation of antigen-presenting cells (APCs) in LNs. Compared with free melittin, α-melittin-NPs markedly enhance LN accumulation and activation of APCs, leading to a 3.6-fold increase in antigen-specific CD8 + T cell responses. Furthermore, in a bilateral flank B16F10 tumor model, primary and distant tumor growth are significantly inhibited by α-melittin-NPs, with an inhibition rate of 95% and 92%, respectively. Thus, α-melittin-NPs induce a systemic anti-tumor response serving as an effective LN-targeted whole-cell nanovaccine.

multidisciplinary sciences
Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines

Kenji Kubara,Kazuto Yamazaki,Takayuki Miyazaki,Keita Kondo,Daisuke Kurotaki,Tomohiko Tamura,Yuta Suzuki

DOI: https://doi.org/10.1016/j.ymthe.2024.01.020

IF: 12.91

2024-01-01

Molecular Therapy

Abstract:mRNA vaccines are promising for cancer treatment. Efficient delivery of mRNAs encoding tumor antigens to antigen-presenting cells (APCs) is critical to elicit anti-tumor immunity. Herein, we identified a novel lipid nanoparticle (LNP) formulation, L17-F05, for mRNA vaccines by screening 34 ionizable lipids and 28 LNP formulations using human primary APCs. Subcutaneous delivery of L17-F05 mRNA vaccine encoding Gp100 and Trp2 inhibited tumor growth and prolonged the survival of mice bearing B16F10 melanoma. L17-F05 efficiently delivered mRNAs to conventional dendritic cells (cDCs) and macrophages in draining lymph nodes (dLNs). cDCs functioned as the main APCs by presenting antigens along with enhanced expression of co-stimulatory molecules. Macrophages triggered innate immune responses centered on type-I interferon (IFN-I) in dLNs. Lymph node (LN) macrophage depletion attenuated APC maturation and anti-tumor activity of L17-F05 mRNA vaccines. Loss-of-function studies revealed that L17-F05 works as a self-adjuvant by activating the stimulator of interferon genes (STING) pathway in macrophages. Collectively, the self-adjuvanticity of L17-F05 triggered innate immune responses in LN macrophages via the STING-IFN-I pathway, contributing to APC maturation and potent anti-tumor activity of L17-F05 mRNA vaccines. Our findings provide strategies for further optimization of mRNA vaccines based on the innate immune response driven by LN macrophages.

genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Yingying Hu,Lin Lin,Jie Chen,Kai Hao,Sijia Zhang,Xiaoya Guo,Zhaopei Guo,Huayu Tian,Xuesi Chen

DOI: https://doi.org/10.1021/acsami.0c12734

2020-08-18

Abstract:Weak T cell responses and immune checkpoints within tumors could be two key factors for limiting antitumor efficacy in the field of cancer immunotherapy. Thus, the combined strategy of tumor vaccines and immune checkpoint blockade has been widely studied and expected to boost antitumor immune responses. Herein, we first developed a two-barreled strategy to combine the nanovaccine with a gene-mediated PD-L1 blockade. On the one hand, polyethyleneimine (PEI) worked as a vaccine carrier to codeliver the antigen ovalbumin (OVA) and the adjuvant unmethylated cytosine-phosphate-guanine (CpG) to formulate the PEI/OVA/CpG nanovaccine through electrostatic binding, which realized both dendritic cell activation and antigen cross-presentation enhancement. On the other hand, the PD-L1 silence gene was loaded by PEI to form PEI/pshPD-L1 complexes, which were further in situ shielded by aldehyde-modified polyethylene glycol (OHC-PEG-CHO) via pH-responsive Schiff base bonds. The formed pshPD-L1@NPs could decrease PD-L1 expression on the tumor cells. However, such a combined two-barreled strategy improved feebly for tumor inhibition in comparison with monotherapy, exhibiting the antagonistic effect, which might be due to the limited T cell response enhancement in the tumor microenvironment. To solve this problem, we have further developed a three-barreled strategy to combine oral administration of l-arginine, which worked as an amplifier to induce robust T cell response enhancement, without causing the upregulation of other negative immune regulators. Superior antitumor behavior and tumor rechallenge protection were realized by the three-barreled strategy in B16F10-OVA (B16-OVA)-bearing mice. The unique three-barreled strategy we developed might offer a novel clinical therapeutic treatment.

materials science, multidisciplinary,nanoscience & nanotechnology
Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Huan Yan,Guibin Lin,Zhanyan Liu,Fei Gu,Yuan Zhang

DOI: https://doi.org/10.1016/j.actbio.2023.02.034

IF: 10.633

2023-03-16

Acta Biomaterialia

Abstract:Immunostimulatory cues play an important role in priming antitumor immunity and promoting the efficacy of subunit cancer vaccines. However, the clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote vaccine efficacy, we develop vaccine formulations which integrate three key elements: (1) a nano-adjuvant formulated by conjugating an agonistic anti-CD40 monoclonal antibody (αCD40) to the surface of a polyIC-loaded lipid nanoparticle, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope that derived from a melanoma antigen gp100, (3) an agonistic anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In a syngeneic mouse model of melanoma, the vaccine formulations enhanced innate immunity and activated multiple innate immune signaling pathways within draining lymph nodes, as well as promoted antigen-specific immune responses and reduced immunosuppression in the tumor microenvironment, leading to profound tumor growth inhibition and prolonged survival. Thus, our vaccine formulations represent an attractive strategy to stimulate antitumor immunity and control tumor progression. Statement of significance The clinical use of many immunostimulatory agents is often hampered by their inefficient in vivo delivery which may decrease immune response to the vaccination. To promote the antitumor immunity of subunit vaccines, we develop novel vaccine formulations that integrate multifunctional modalities including (1) a nano-adjuvant containing anti-CD40 monoclonal antibody (αCD40) and TLR3 agonist which activate innate immunity through diverse signaling pathways, (2) a peptide amphiphile containing an optimized CD8 + T-cell epitope from tumor antigen, (3) an anti-4-1BB monoclonal antibody (α4-1BB) that boosts the efficacy of vaccinations. In this study, our vaccine formulations stimulate superior antitumor immunity and control tumor progression. The above nano-engineered platform and immunogenic biomacromolecules can be further applied to other T-cell-inducing vaccines.

engineering, biomedical,materials science, biomaterials
Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy

Mei Hu,Jiao Zhang,Li Kong,Yulin Yu,Qian Hu,Ting Yang,Yi Wang,Kun Tu,Qi Qiao,Xianya Qin,Zhiping Zhang

DOI: https://doi.org/10.1021/acsnano.0c09681

IF: 17.1

2021-01-20

ACS Nano

Abstract:Exploring a rational delivery system of integrating chemotherapy with immunotherapy to broaden benefits of cancer immunochemotherapy is still under challenge. Herein, we developed doxorubicin (DOX)-loaded biomimetic hybrid nanovesicles () via fusing artificial liposomes (LIPs) with tumor-derived nanovesicles (TNVs) for combinational immunochemotherapy. with a homologous targeting ability could deliver DOX to tumor tissue and elicit an effective immunogenic cell death response to improve the immunogenicity of a tumor. Meanwhile, the preserved tumor antigens and endogenous danger signals in activated dendritic cells and induced a subsequent antigen-specific T cell immune response. displayed a specific antitumor effect on murine melanoma, Lewis lung cancer, and 4T1 breast cancer based on the infiltration of effector immune cells and improvement of the immunosuppressive tumor microenvironment. Furthermore, the combination of with immune checkpoint inhibitor amplified antitumor efficacy with 33.3% of the mice being tumor-free. Therefore, the hybrid LINV is a promising drug delivery platform with a boosted antitumor immune response for effective immunochemotherapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c09681?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c09681</a>.Additional in vitro characterization, interaction of on tumor cells and DC2.4, quantitative analysis, in vivo ICD vaccine, in vivo T cell priming, in vivo antitumor effect, flow cytometry and ELISA assays, HE staining, immunofluorescence, and immunohistochemistry assay (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c09681/suppl_file/nn0c09681_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma

Yanhong Chu,Lingyu Qian,Yaohua Ke,Xiaoyu Feng,Xinjie Chen,Fangcen Liu,Lixia Yu,Lianru Zhang,Yaping Tao,Rui Xu,Jia Wei,Baorui Liu,Qin Liu

DOI: https://doi.org/10.1186/s12951-022-01397-7

IF: 10.2

2022-04-13

Journal of Nanobiotechnology

Abstract:Abstract Background Neoantigens are considered ideal targets for immunotherapy, especially tumor vaccine, because of their strong specificity and immunogenicity. Here, we developed a neoantigen nanovaccine used liposomes with lymph-node targeting characteristic. Methods Our nanovaccine was composed of neoantigens, an amphiphilic liposome and an adjuvant MontanideTM ISA 51. Small animal imaging system and immunofluorescence staining were used to identify the distribution of nanovaccines. A subcutaneous-tumor-resection mouse model of melanoma was established to evaluate the anti-tumor efficacy. Flow cytometry was performed to assay the immune responses initiated by nanovaccines. Results Nanovaccines could traffic to lymph nodes, be uptaken by CD11c + DCs and promote DCs maturity. After the treatment of our neoantigen nanovaccines, the average recurrence time was extended from 11 to 16 days and the median survival time was even prolonged 7.5 days relative to the control group (NS group). Nanovaccines increased neoantigen-specific T cells to 10-fold of free vaccines, and upregulated Th1 cytokines, such as IFN-γ and TNF-α. The anti-tumor activity of spleen lymphocytes in the nanovaccine group was significantly stronger than that of other groups. However, some immune-inhibitory cells or molecules in tumor microenvironment have been detected upregulated under the immune pressure of neoantigen nanovaccines, such as Tregs and PD-L1. The efficacy of the neoantigen nanovaccine combined with anti-PD1 antibody or Treg inhibiting peptide P60 was better than that of the single treatment. Conclusions We developed a general vaccine strategy, triggering specific T cell responses, and provided feasible combination strategies for better anti-tumor efficacy. Graphical abstract

biotechnology & applied microbiology,nanoscience & nanotechnology
Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy

Yunfeng Yan,Xiaomin Liu,Longyu Wang,Chengfan Wu,Qi Shuai,Yanmei Zhang,Shuai Liu

DOI: https://doi.org/10.1016/j.biomaterials.2023.122279

IF: 14

2023-10-01

Biomaterials

Abstract:Efficient and safe delivery of vulnerable mRNA is a long-standing challenge for the broad application of the emerging mRNA-based therapeutics. Herein, a combinatorial library containing 119 novel lipids was constructed via sequential aza-Michael addition reactions of arylates and varying amines to tackle the ongoing challenge in mRNA delivery. Through in vitro screening of the lipid library on IGROV 1 cells, we identified several synthetic lipids with superior mRNA delivery efficacy. The delivery capability of these lipids was verified by the potent expression of luciferase in BALB/c mice upon intravenous administration of luciferase-encoding mRNA lipid nanoparticles (LNPs). Further investigations on the structure-activity relationship revealed that lipids with branched hydrophobic tails were better at delivering mRNA than those containing linear tails at the similar total number of carbons. In comparison to linear tails, the branched tails endowed LNPs with less inner hydrophobicity, fewer surface charges, and proper stability, which benefits the cellular uptake of LNPs and the intracellular trafficking of mRNA, thus improves the delivery efficacy of mRNA. The therapeutical potential of the lead LNPs was evaluated by delivering ovalbumin (OVA)-encoding mRNA to mice bearing B16-OVA melanoma tumors. The results demonstrated that the administration of OVA mRNA LNPs significantly activated CD8+ T cells in tumor microenvironment and substantially prohibited the growth of the aggressive B16-OVA tumors. The robust antitumor efficacy highlights the great potential of these LNPs in cancer immunotherapy.

engineering, biomedical,materials science, biomaterials

Breast reconstruction: sorting out the options.

Abstract B049: Lipid nanoparticle-delivered toll-like receptor agonists are highly effective in cancer immunotherapy

Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy Against Metastatic Tumors

Parenterally acquired non-A non-B hepatitis ten years on: advances in diagnosis and therapy.

Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors.

Modulating Elasticity of Liposome for Enhanced Cancer Immunotherapy

A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer

Temperature sensitive liposome based cancer nanomedicine enables tumour lymph node immune microenvironment remodelling

Abstract 6740: Next-generation LNPs induce effective anti-tumor T cell responses

Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Lymph Node Delivery Strategy Enables the Activation of Cytotoxic T Lymphocytes and Natural Killer Cells to Augment Cancer Immunotherapy.

Cationic Lipids‐Mediated Dual‐Targeting of Both Dendritic Cells and Tumor Cells for Potent Cancer Immunotherapy

Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity

Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity

Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response

Lymph node macrophages drive innate immune responses to enhance the anti-tumor efficacy of mRNA vaccines

Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l -Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade

Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles

Immunogenic Hybrid Nanovesicles of Liposomes and Tumor-Derived Nanovesicles for Cancer Immunochemotherapy

Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma

Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy